The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Myopericarditis (see under XIIc/d/g)
Publications
Mesalamine-Induced Myopericarditis: A Case Report and Literature Review.
Cardiology research. 2019;10(1):59-62
Recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis.
BMJ case reports. 2019;12(2)
Recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis.
Journal of cardiovascular ultrasound. 2012;20(3):154-6
Recurrent myopericarditis with extensive ulcerative colitis.
The Canadian journal of cardiology. 2010;26(10):549-50
Mesalazine-induced myopericarditis in a patient with ulcerative colitis.
International journal of colorectal disease. 2006;21(2):199-200
The lung in inflammatory bowel disease.
Medicine. 1993;72(3):151-83